Figure 2
Figure 2. Survival of CN-AML patients 60 years of age or older, according to ASXL1 mutation status. (A) DFS. (B) OS. (C) EFS.

Survival of CN-AML patients 60 years of age or older, according to ASXL1 mutation status. (A) DFS. (B) OS. (C) EFS.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal